BioXcel reports preliminary Q2 2024 IGALMI net revenue of $1.1M, up 90% QoQ

BioXcel Therapeutics, Inc.

2024-Q2 EPS reported -$0.99 revenue$1,686,000

Preliminary Q2 2024 net revenue from IGALMI approximately $1.1M, up 90% from Q1 2024 and 141% from Q2 2023.
Growth driven by increased contracting with psychiatric clinics and behavioral health facilities via small commercial team.
CEO cites potential for at-home expansion if BXCL501 approved, targeting estimated 23M annual agitation episodes.
Full Q2 2024 financial results and business update to be discussed on a future earnings call (date TBD).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.